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a  b  s  t  r  a  c  t
Leishmaniasis  is  one  of  the most  serious  worldwide  diseases  caused  by  protozoan  parasites  of  the  Leish-
mania  genus,  affecting  millions  of  people  around  the  world.  All  currently  available  treatments  present
severe  toxic  side  effects,  require  long-term  compliance,  cause  serious  side  effects  and  are  uncomfort-
able  for  patients.  Leishmania  amazonensis,  a species  endemic  to  Brazil,  causes  severe  localised  or  diffuse
skin  lesions  in humans.  Owing  to  the  unsatisfactory  nature  of the  currently  available  chemotherapies,
new  approaches  have  been  assessed  for improved  therapeutic  intervention  strategies  against  leishma-
niasis.  Miltefosine  is  an  alkylphospholipid  analogue  that  exhibits  potent  activity  against  the  different
clinical  manifestations  of  leishmaniasis.  Thus,  the  aim  of  this  study  was  to  investigate  the  long-term
efﬁcacy  of  miltefosine  in  BALB/c  mice  infected  with  L.  amazonensis  owing  to  the  lack  of  a  profound
study  demonstrating  its dose-dependent  and  long-term  effects.  It was  observed  that  animals  treated
with  20–50  mg/kg/day  of  miltefosine  exhibited  a signiﬁcant  dose-dependent  reduction  in  lesion  size;
furthermore,  in  mice  receiving  higher  doses,  lesions  disappeared  after  the  end  of treatment.  To  conﬁrm
a  possible  parasitological  cure,  mice  up  to 250  days  after  the  end  of treatment  were  analysed.  No  lesions
or  presence  of  parasite  DNA  were  found  in  mice  treated  with  30,  40 and  50 mg/kg/day  of  miltefosine.  In
summary,  these  results  show  that miltefosine  may  be used  to  treat  cutaneous  leishmaniasis  caused  by  L.
amazonensis,  alone  or as combination  therapy.
nd th© 2011 Elsevier B.V. a
. Introduction
Leishmaniasis is a complex of mammalian diseases caused by
rotozoan parasites of the Leishmania genus, infecting over 12 mil-
ion people around the world [1]. A total of 21 Leishmania spp. have
een described and together they are responsible for the three main
linical manifestations of leishmaniasis, namely cutaneous, muco-
utaneous and visceral leishmaniasis. Leishmania amazonensis is an
mportant species in Brazil that is capable of producing a wide spec-
rum of human diseases, including the diffuse (anergic) cutaneous
eishmaniasis (CL) that is highly mutilating and incurable using
urrently available forms of treatment [2,3].
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Although the treatment for leishmaniasis was introduced in
the early 20th century, parenteral administration of pentava-
lent antimony compounds (meglumine antimoniate and sodium
stibogluconate) remains the ﬁrst-choice treatment for all forms
of leishmaniasis [4]. In the case of antimonial resistance, the
second-choice treatment includes pentamidine and amphotericin
B (deoxycholate or liposomal formulation) [4]. However, each of
these therapies presents important limitations, including long-
term parenteral administration, toxic side effects, high cost in
endemic countries, and a high number of resistance cases pre-
dominately associated with human immunodeﬁciency virus (HIV)
co-infection [4]. Thus, these drugs are unsatisfactory and there is an
urgent need to identify novel compounds or therapeutic strategies
that are more safe, accessible and less toxic.
Miltefosine, a hexadecylphosphocholine, was  initially studied
Open access under the Elsevier OA license.as an anti-tumour agent [5]; more recently, it was  described
to exhibit both in vitro and in vivo activity against Leishma-
nia parasites [6–11]. Oral administration of miltefosine has been
used in India to treat visceral leishmaniasis (VL) since 1998.
ess under the Elsevier OA license.
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Fig. 1. In vivo efﬁcacy of Glucantime® and oral miltefosine (MLT) treatment in BALB/c mice infected with Leishmania amazonensis. Infection and treat-
ment  are described in Sections 2.1 and 2.2. (A) Dose–response curve of MLT treatment. (B) Showing the signiﬁcant effects of MLT  after 9 days and 21
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10% foetal bovine serum at 25 ◦C. Following transformation, sta-
tionary promastigotes (5 days of culture in Warren’s medium) wereays  of treatment. Lesion sizes were monitored weekly. Values are the me
eviation.  *P < 0.05 comparing all doses of Glucantime and MLT  with the control gro
urrently, it is recommended in India and Ethiopia to treat VL
nd in Colombia, Bolivia and Guatemala to treat CL [12–19]. In
razil, recent studies demonstrated that miltefosine is also efﬁcient
gainst infections caused by Leishmania braziliensis [20], Leish-
ania guyanensis [21] and Leishmania chagasi [22]. Miltefosine
an be considered less severe than the other drugs, however it
resents some important side effects such as gastrointestinal dis-
rders and teratogenicity [23,24]; thus, it is not recommended
or women of fertile age. Although several works have demon-
trated the efﬁcacy of miltefosine, it remains an interesting
ompound to investigate its activity against different Leishmania
pp., particularly species associated with cutaneous infections in
razil.
Thus, the present study investigated the efﬁcacy of miltefo-
ine treatment for experimental CL in L. amazonensis-infected
ALB/c  mice using seven doses varying from 2.5 mg/kg/day to
0 mg/kg/day and treatment lasting 21 days. To conﬁrm the long-
erm efﬁcacy of miltefosine, treated mice were evaluated 250 days
fter treatment ended by measurement of lesion size, skin smears
nd quantitative polymerase chain reaction (qPCR).f lesion sizes in ﬁve mice in each group and bars represent the standard
2. Materials and methods
This  study (protocol no. IBCCF 096/097) was approved by the
Ethics Committee for Animal Experimentation of the Health Sci-
ences Centre, Federal University of Rio de Janeiro (Brazil). All
animals received humane care in compliance with the ‘Principles of
laboratory animal care’ formulated by the National Society for Medi-
cal Research and the ‘Guide for the care and use of laboratory animals’
prepared by the National Academy of Sciences (Washington, DC).
2.1. Parasites and infections
Amastigotes  of L. amazonensis WHOM/BR/75/Josefa strain were
isolated from footpad nodules of infected BALB/c mice and were
transformed into promastigotes in Warren’s medium containingused to inoculate 5-week-old female BALB/c mice weighing ca. 20 g.
A  total of 60 mice were trichotomised at the base of the tail and were
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Fig. 2. Images of lesions during treatment of BALB/c mice infected with Leishmania
amazonensis. Photographs were taken on the ﬁrst and last days of treatment and
100 days after the end of treatment. In the control, vehicle control and Glucantime®
groups, the lesions showed an intense swelling and ulcerated by 100 days after
treatment  cessation. In groups treated with miltefosine at doses ≥20 mg/kg/day,
the  photographs revealed a complete healing of the nodules and ulcers.ntimicrobial Agents 39 (2012) 326– 331
then inoculated with ca. 1.0 × 107 infective promastigotes/mouse
by  subcutaneous injection.
2.2.  Treatment of infected mice
Treatment was  initiated when the lesions reached a diameter
of 5–7 mm  (ca. 10 mm2 lesion area), which in this experiment was
exactly 4 weeks post infection. This initial condition of lesion size
is important to mimic the real-life scenario when patients seek
treatment services. A dose–response study with miltefosine (Cay-
man Chemical Co., Ann Arbor, MI)  was carried out compared with
meglumine antimoniate (Glucantime®; Aventis, São Paulo, Brazil)
(a gift from the Health Secretary of Rio de Janeiro, Brazil) as a
standard treatment. Miltefosine was  administered by oral gavage,
whilst Glucantime was  given by intraperitoneal injection. Treat-
ments were administered daily for 21 days. Stock solutions of
miltefosine were prepared in polyethylene glycol 200 (PEG200)
(Sigma, St Louis, MO), whilst Glucantime was  diluted in water; both
solutions were stored at 4 ◦C.
Following lesion development, mice were selected according
to lesion size to ensure similar levels of infection and were then
divided into ten groups (ﬁve mice per group). Treatment groups
were as follows: control group treated with water; vehicle con-
trol group treated with PEG200; Glucantime group treated with
50 mg/kg/day Glucantime; and seven miltefosine groups treated
with seven different doses of miltefosine (2.5, 5, 10, 20, 30, 40 and
50 mg/kg/day).
2.3.  Treatment evaluation
Treatment  efﬁcacy was evaluated using three different parame-
ters: (i) lesion size; (ii) lesion parasite burden as determined by
Giemsa-stained skin smears; and (iii) tissue parasite burden as
determined by real-time qPCR. During treatment, lesion size was
monitored weekly using a calliper (Mitutoyo, Taipei, Taiwan) to
determine the lesion diameter. In addition, weekly pictures of the
lesions were taken. Lesion size was  determined by obtaining the
average value between horizontal and vertical directions, and the
ulcer area was  expressed in mm2. Skin smears were made on
glass slides, ﬁxed with absolute methanol, stained with Giemsa
and observed using a Zeiss Axioplan light microscope (Carl Zeiss,
Oberkochen, Germany) to check for the presence of amastigotes or
infected macrophages.
To  conﬁrm the long-term efﬁcacy and a possible parasitologi-
cal cure of the miltefosine-treated mice, the different groups were
followed for 250 days after the end of treatment. Mice were consid-
ered cured if lesions and ulcers were completely absent 100 days
after the end of treatment.
2.4.  Quantiﬁcation of tissue parasite burden by quantitative
polymerase chain reaction
Quantiﬁcation  of tissue parasite load was done by qPCR using
a 7500 Real-Time PCR System (Applied Biosystems, Foster City,
CA) according to the manufacturer’s instructions. DNA was  isolated
from lesions of infected mice at the end of the 21-day treat-
ment period and also at 100 days and 250 days post treatment
as described previously [25]. Brieﬂy, samples were digested with
200 g/mL proteinase K in 10 mM Tris–HCl (pH 7.6), 0.1 M NaCl,
10 mM ethylene diamine tetra-acetic acid (EDTA) and 0.5% sodium
dodecyl sulphate (SDS) for 2 h at 55 ◦C. Next, phenol–chloroform
extraction  and ethanol precipitation were performed according to
standard protocols. For qPCR assays, samples were run in triplicate,
where 1 ng of total DNA was  added to a 15 L reaction mixture
containing Power SYBR Master Mix  (Applied Biosystems). qPCR
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Fig. 3. Parasite burden throughout the course of treatment. Skin smears were taken from all experimental groups, stained with Giemsa and observed under a light microscope:
(A) control; (B) vehicle control; (C) Glucantime 50 mg/kg/day; (D) miltefosine 2.5 mg/kg/day; (E) miltefosine 5 mg/kg/day; (F) miltefosine 10 mg/kg/day; (G) miltefosine
20 mg/kg/day; (H) miltefosine 30 mg/kg/day; (I) miltefosine 40 mg/kg/day; and (J) miltefosine 50 mg/kg/day. In the control and vehicle control groups and those treated with
Glucantime® or miltefosine at doses of 2.5 mg/kg/day and 5 mg/kg/day groups, the skin smears appeared densely parasitised (A–E). In the group that received miltefosine
at a dose of 10 mg/kg/day, few parasites were observed in the many ﬁelds that were searched (F). No parasites were seen in the groups treated with miltefosine at doses
≥20 mg/kg/day (G–J). Bars, 50 m.
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wonditions were as follows: 55 ◦C for 2 min, 95 ◦C for 10 min  and 40
ycles of 95 ◦C for 30 s and 58 ◦C for 60 s. Leishmania 18S RNA (5′-
CCGCCCGTCGTTGTTT-3′ and 5′-CACCGCCTGTCCGATCAC-3′) and
ouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (5′-
TCTGATCTCAGCTCCCCTGTT-3′ and 5′-CCAGGCGCCCAATACG-3′)
rimers were used. Puriﬁed DNA from L. amazonensis and mice
as used for calibrating standard curves. The efﬁciency and speci-
city of the PCR reaction were evaluated using serial dilutions
f each template DNA and melt curve analysis. The amount
f DNA in the samples was determined using 7500 Sequence
etection Software (Applied Biosystems) by interpolating the
hreshold cycle (Ct) of each sample in the corresponding standard
urve.
.5. Statistical analysis
The  statistical signiﬁcance of differences in the average lesion
iameters amongst groups was evaluated using the one-way anal-
sis of variance (ANOVA) test followed by Tukey’s test (GraphPad
rism 5 software; GraphPad Software Inc., La Jolla, CA). Differences
ere considered signiﬁcant when P-values were <0.05.3. Results and discussion
Treatment  started at 4 weeks post infection when lesions
were established and apparent. All mice in the treatment groups
exhibited similar-sized lesions. Over the course of treatment,
lesions grew normally according to the course of infection in
the control and vehicle groups that did not receive treatment. In
Glucantime-treated mice, lesion size decreased during treatment.
In the groups that received oral miltefosine, the response was
dose-dependent, with a reduction in lesion size during the 21-day
treatment period (Fig. 1). For doses >5 mg/kg/day, the reduction in
lesion size was statistically signiﬁcant at 21 days after the end of
treatment (Fig. 1B). Mice treated with 2.5 mg/kg/day of miltefosine,
which is the dose recommended by the World Health Organization
(WHO) and used to treat human VL, were similar to mice treated
with 50 mg/kg/day Glucantime (Fig. 1). Photographs of all groups
on the ﬁrst and last days of treatment revealed the potent effect
of miltefosine against L. amazonensis-infected mice (Fig. 2). In mice
that did not receive treatment (control and vehicle control), lesions
swelled at the infection site (Fig. 2). In the groups treated with Glu-
cantime and with miltefosine at doses of 2.5, 5 and 10 mg/kg/day,
lesions exhibited a smaller amount of swelling at the infection site
330 J.L.P. Godinho et al. / International Journal of A
Fig. 4. Quantitative polymerase chain reaction (qPCR) of Leishmania amazonensis in
skin lesions of infected mice. Assays were performed as described in Section 2.4 and
results are expressed as Leishmania genome equivalents (GEq) per 10 000 mouse
GEq  considering the amount of DNA per cell (0.12 pg in Leishmania [29] and 12 pg in
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oouse [30]). Error bars indicate the standard error. CTRL, control group; CTRL PEG,
reated with polyethylene glycol 200; Glu, treated with Glucantime®; 2.5–50 MLT,
reated with 2.5–50 mg/kg/day of miltefosine.
ompared with the control group at the 21-day treatment period
Fig. 2). Mice treated with miltefosine at doses of 20, 30, 40 and
0 mg/kg/day did not exhibit nodules or ulcers (Fig. 2).
Parasite burden in Glucantime- and miltefosine-treated ani-
als was evaluated by microscopic analysis of skin smears stained
ith Giemsa. At the 21-day treatment period, mice in the con-
rol and vehicle control groups (that received water and PEG200),
espectively, the Glucantime group and the miltefosine groups
hat received doses of 2.5 mg/kg/day or 5 mg/kg/day presented a
arge number of amastigotes inside macrophages at the lesion site
Fig. 3A–E). In mice treated with 10 mg/kg/day of miltefosine, the
umber of amastigotes was signiﬁcantly reduced in comparison
ith the control groups and the groups treated with Glucan-
ime and miltefosine at doses of 2.5 mg/kg/day and 5 mg/kg/day
Fig. 3F). Interestingly, amastigotes were not observed in the skin
mears from mice treated with doses ≥20 mg/kg/day of miltefosine
Fig. 3G–J).
To  conﬁrm the efﬁcacy of miltefosine at the 21-day treatment
eriod, parasite burden was also evaluated by detecting parasite
NA in lesions by qPCR analysis. As depicted in Fig. 4, parasite
urden in Glucantime- and PEG200-treated animals was  reduced
a. three-fold compared with the control group. Treatment with
ig. 5. Lesion appearance 250 days following treatment cessation. Photographs of infect
iltefosine were taken 250 days after treatment was  stopped. These photos demonstrate
f  the tail. At this time, the treated mice appear completely healthy.ntimicrobial Agents 39 (2012) 326– 331
2.5  mg/kg/day of miltefosine reduced parasite burden ca. 10-fold,
whilst miltefosine doses ≥5 mg/kg/day led to parasite DNA levels at
or below the limit of detection. These results were consistent with
the clinical lesion progression shown in Figs. 2 and 3.
During  the 100 days after the end of treatment, lesions in
animals that did not receive treatment and those treated with
Glucantime or miltefosine at doses varying from 2.5 mg/kg/day to
10 mg/kg/day were swelled at the infection site and became ulcer-
ated (Fig. 2), whilst mice treated with miltefosine at doses of 20, 30,
40 and 50 mg/kg/day did not exhibit nodules or ulcers (Fig. 2). How-
ever, skin smears revealed the presence of intracellular amastigotes
in mice treated with doses of 20 mg/kg/day of miltefosine but not in
mice treated with doses of 30, 40 and 50 mg/kg/day of miltefosine
(data not shown).
To  conﬁrm a possible parasitological cure, we decided to inves-
tigate treated mice during 250 days after the end of treatment,
different from other studies that have evaluated the short-term
efﬁcacy of miltefosine against L. amazonensis-infected mice [26].
During this time, lesion appearance was observed. Skin smears and
qPCR were also made and analysed to determine parasite burden.
Fig. 5 depicts lesion development 250 days after treatment was ter-
minated. Complete clinical cure was  observed in mice that received
miltefosine at doses of 30, 40 and 50 mg/kg/day; these mice did not
present any nodules or ulcers and were healthy in appearance. In
addition, qPCR analysis conﬁrmed the clinical cure, where parasite
DNA was  not detected in the tissues collected, including liver and
spleen (data not shown).
Previous  studies demonstrated the efﬁcacy of miltefosine
against murine models of VL caused by Leishmania donovani [10]
and CL caused by Leishmania major [27], Leishmania mexicana [28]
and L. amazonensis [26]; however, these studies evaluated the
short-term efﬁcacy of miltefosine. In animal models, the efﬁcacy
doses are >10 mg/kg/day. Sometimes doses of 20 mg/kg/day or
combination therapy are required to have an effective reduction of
the parasite burden in the liver, spleen and skin [14,30]. Although
mice treated with 50 mg/kg/day of miltefosine were cured, they
presented signs of toxicity, with signiﬁcant weight loss; however,
no animals died during the 21 days of treatment.
In summary, these results showed that at doses ≥30 mg/kg/day,
miltefosine is efﬁcacious in the treatment of L. amazonensis-
infected mice. Effective cure was observed at miltefosine doses of
30, 40 and 50 mg/kg/day after 250 days of observation, which was
conﬁrmed by qPCR analysis. Thus, miltefosine remains a promis-
ing compound to use against the different clinical manifestations
of leishmaniasis. Furthermore, as its side effects could be consid-
ered minimal compared with the effects observed for Glucantime,
ed mice treated with (A) 30 mg/kg/day, (B) 40 mg/kg/day and (C) 50 mg/kg/day of
 a clinical healing of the infection, where no nodules or ulcers were seen at the base
al of A
p
c
s
c
f
A
o
R
D
d
C
r
(
a
t
(
‘
S
l
(
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[J.L.P. Godinho et al. / International Journ
entamidine and amphotericin B, it could be utilised alone or in
ombined therapy to reduce the therapeutic dose. Therefore, this
tudy conﬁrmed the long-term efﬁcacy of miltefosine to treat CL
aused by Brazilian species of Leishmania, thus supporting the need
or the advancement of miltefosine clinical trials.
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